Next generation hybrid nanomaterials: bispecific antibody-targeted polymers (2016–2019)
Hybrid materials consisting of nanomaterials and biomolecules form the basis of many of the diagnostic devices used commercially. This project aims to develop and optimise a novel platform technology for facile conjugation of nanomaterials with antibodies that is stable under physiological conditions. A novel antibody developed by Minomic, MIL38, will provide the testbed for the technology. This project has the potential to rapidly improve the ligation process between synthetic nanomaterials and biologics, leading to more efficient synthesis of targeted diagnostics. This will provide a significant commercial advantage for any nanomaterials developed for the field, and specifically for this project, expedite translation of MIL38.